NASAL sprays containing the hormone oxytocin, nicknamed the "cuddle chemical"
because it helps mothers bond with their babies, have helped people with schizophrenia.
Although the 15 participants used the sprays for three weeks only, most reported measurable improvements in their symptoms in this the first trial to test oxytocin in schizophrenia. "It's proof of concept that there's therapeutic potential here," says David Feifel at the University of California in San Diego, head of the team running the trial.
Most participants reported measurable improvements in the first ever trial to test oxytocin in schizophreniaEach participant received oxytocin or a placebo for three weeks, then the opposite treatment for three weeks with a week break in between.
On the basis of two standard tests for schizophrenia, taken before and after each block of treatment, participants averaged improvements of around 8 per cent when taking the oxytocin compared with the placebo (Biological Psychiatry, DOI: 10.1016/j.biopsych.2010.04.039).
The effects didn't kick in until the final week, suggesting that it takes a while for the hormone to begin acting. "Standard antipsychotic drugs increase their efficacy several weeks later too, so oxytocin fits that profile," says Feifel.
Feifel thinks that oxytocin is dampening down the excessive production of the neurotransmitter dopamine, which can trigger schizophrenic symptoms such as hallucinations. He says the rationale for treating people came from his own team's studies showing that oxytocin could relieve a form of psychosis in mice, and research showing that people who sniffed nasal sprays of oxytocin became more trusting, which could ease paranoia symptoms in schizophrenia.
Feifel is seeking approval from the US National Institutes of Health for a larger trial testing oxytocin at a range of doses, and over a longer time.
"This work provides compelling data on the utility of oxytocin as a treatment for schizophrenia," says Heather Caldwell of Kent State University in Ohio, co-author of a study in 2008 showing that "knockout" mice unable to make oxytocin were more prone to a form of psychosis.
- New Scientist
- Not just a website!
- Subscribe to New Scientist and get:
- New Scientist magazine delivered to your door
- Unlimited online access to articles from over 500 back issues
- Subscribe Now and Save
If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.
Have your say
Only subscribers may leave comments on this article. Please log in.
Compelling?
Fri Jul 16 14:47:13 BST 2010 by Allan Brewer
Actually I wouldn't say "8% improvement" was "compelling data".
Compelling?
Fri Jul 16 21:44:34 BST 2010 by allenallen
Yes, one wonders.... 8% fewer voices in their heads or were the voices 8% nicer in tone?
All comments should respect the New Scientist House Rules. If you think a particular comment breaks these rules then please use the "Report" link in that comment to report it to us.
If you are having a technical problem posting a comment, please contact technical support.
Monday 19 July 2010
'Cuddle chemical' eases symptoms of schizophrenia
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment